Palatal Position of Patient Tracker for Magnetic Neuronavigation System: Technical Note.

OBJECTIVE: Recently, the neuronavigation system (NS) has become an essential intraoperative tool for many neurosurgical procedures, allowing for precise lesion localization. It is particularly important to avoid errors during the navigation process. Here we report a novel technique using palatal positioning of the patient tracker to ensure optimal accuracy during magnetic navigation in various neurosurgical procedures. METHODS: This retrospective study included a total of 34 patients treated in our institution between June 2017 and January 2018. The patients were split into 2 groups who underwent surgery under general anesthesia: a microscopic transcranial group and an endoscopic endonasal group. Preoperative and postoperative navigation accuracy was assessed by 2 neurosurgeons. RESULTS: After our surgical planning navigation protocol was applied, both transcranial and endonasal procedures were successfully performed under navigation guidance in all but 1 patient. There were no intraoperative or postoperative complications related to the tracker mounted under the hard palate. In 33 cases a maximal tracking view and optimal navigation accuracy was achieved, for a success rate of 97%. CONCLUSIONS: The positioning of the patient tracker under the hard palate proved safe, accurate, and feasible in 97% of our patients. In our case series, it met the main goal of avoiding device displacement without a sense of invasiveness and postoperative patient discomfort.

Effects of formoterol inhaled dry powder on exercise performance in chronic obstructive pulmonary disease: a single-center, randomized, double-blind, placebo-controlled, crossover study.

BACKGROUND: Inhaled bronchodilators commonly are used to reduce the work of breathing in patients with chronic obstructive pulmonary disease (COPD). The effects of bronchodilators are assessed in terms of symptom relief and/or improvements in spirometric indices. However, disability in COPD patients also is related to determinants such as exercise tolerance, which cannot be predicted on the basis of respiratory function. The effect of bronchodilators, such as inhaled beta2-agonists, on exercise performance of COPD patients needs to be tested. OBJECTIVE: This study investigated the effects of formoterol inhaled dry powder on exercise performance assessed using the shuttle walking test (SWT) in patients with mild to moderate COPD. METHODS: Patients having COPD with mild to moderate airway obstruction performed a pulmonary function test and an SWT before and after inhalation, on 2 consecutive days, of formoterol 12 µg or placebo, given by dry powder inhaler, according to a double-blind, placebo-controlled, crossover study design. Breathlessness was measured using the Borg scale (BS) and a visual analog scale at baseline and after an SWT. RESULTS: Twenty patients (15 men, 5 women; mean [SD] age, 65.95 [8.32] years) were included in the study. Forced expiratory volume in 1 second (FEV1) (P = 0.009), forced mid-expiratory flow (FEF25-75) (P = 0.011), and SWT (P = 0.005) improved significantly more with formoterol than placebo. Breathlessness decreased with formoterol, but the difference compared with placebo was statistically significant only when measured using the BS (P = 0.023). In the pooled placebo and formoterol tests, changes in the SWT were unrelated to changes in FEV1 (r = 0.18) and in FEF25-75 (r = 0.31). CONCLUSIONS: The results of this study showed that formoterol inhaled dry powder significantly improved exercise performance in patients with COPD and that this effect was at least partially independent of achieved bronchodilation. A larger cohort of patients should be studied and a more comprehensive protocol performed to verify whether the increase in exercise tolerance after administration of formoterol is related to a decrease in expiratory flow limitation during exercise and/or to systemic effects of the drug. Another issue to be clarified is whether the improvement in exercise capacity can significantly decrease disability in patients with severe COPD.